1. Multiplex Biosensor That Accurately Detects & Identifies
Viruses & Bacteria In Under 60 Seconds
1
Including COVID-19, Influenza, RSV, & Strep

2. The Guessing & Waiting Game: The Dual Challenge in Respiratory Diagnostics
Doctors typically rely on educated
guesswork to provide treatment.
Over 70%of those
infections are treated
based on symptoms, not
precise diagnosis.
24-72 hours is the
average result time, severely
delaying targeted treatment.
Current comprehensive diagnostic
methods are slow & expensive.
Slow and expensive diagnostics leads to educated guesswork in the treatment of respiratory infections.
Patient presents respiratory
infection symptoms.
Over 100 Million
respiratory infections
occur in the U.S. each year.
2

3. Consequences of the Guessing Game in Treatment
Non-targeted or incorrect treatment can lead to dire consequences.
Of the 100 million
respiratory infections
over 20 Million
are hospitalized.
Of the 100 million,
47 Millionare
incorrectly prescribed
antibiotics.
Of the 20 million patients
hospitalized, there are
1 Milliondeaths.
“[Without] antibiotics …we’ll
lose the most powerful tool
we have to fight life-
threatening infections.”
CDC Director Tom Frieden, M.D., M.P.H.
Antibiotic Resistance
3

4. Solution: Fast, Affordable Precision Point-of-Care Diagnostics
Saves countless lives & reduces antibiotic resistance.
Every symptomatic patient
receives an immediate,
comprehensive diagnostic
eliminating PoC uncertainty:
50% reduction in
the hospitalizations.
30% reduction in
the hospitalization
deaths.
75% reduction in
the inappropriate
antibiotic Rx.
4

5. Introducing Opteev’s Biosensor: the Future of Pathogen Detection
Through our groundbreaking, patent-pending* impedance-based detection technology,
we bring you a complete paradigm shift in rapid comprehensive pathogen diagnostics.
Results In Under
60 Seconds.
Accurate
Detects a wide range of
pathogens from COVID/Flu/RSV
to foodborne, GI, STD, & more.
Lightning Fast
Versatile Revenue Streams
Multiple Market Applications
Low Cost & Scalable
Adaptable for Future Threats
From Point-of-Care Diagnostics
to At-Home Testing, Air Quality
Monitoring, & Food Safety.
Over 99.49% accurate
with an impressive LoD.
Economically designed for broad
accessibility & scalable for efficient
production to meet vast demand.
Easily adaptable to detect novel
pathogens as soon as genetic
sequencing data is made available.
*Patent Application #63/513,007
5

6. How Opteev’s Biosensor Works
Opteev’s biosensor technology precisely detects and differentiates multiple pathogens at such lightning-
speed by utilizing a combination of biogenic functionalization, impedance detection, and A.I.-processing.
Opteev’s Multi-Target
Biosensor is an A.I.-
powered biochip consisting
of multiple rows of
functionalized biosensors
that each target a specific
pathogen.
Multiple Biosensors
On A Single Biochip
Each of the individual
biosensors are
functionalized with a binding
layer (peptides, antibodies,
or biogenic material) that
specifically binds to the
targeted pathogen.
Functionalized for
Precision & Accuracy
A.I.-Powered
Biosensing
As pathogens encounter their
unique biogenic match in the
Biosensor, a change in
electrical parameters triggers
instant detection. This
electrical data is sent to the
A.I. processor for instant
analysis.
Lightning-Fast
Impedance Detection
Artificial Intelligence
supercharges the
Biosensor’s peptide-
functionalized accuracy &
precision, eliminating
background noise and
delivering results at
unparalleled speeds.
1 2 3 4
6

7. Ready for the Unknown: Adaptable for Emerging Threats
Opteev’s multiplex diagnostic is an agile technology platform that can leverage genetic
sequencing data to provide immediate and accurate diagnostics for emerging and novel viruses.
As soon as genetic data is available for a novel virus, Opteev’s
biosensor can be configured to detect that virus in almost real-time!
Opteev’s Multiplex Diagnostic Platform will provide
public health agencies the ultimate tool for surveillance,
containment, and treatment of future outbreaks.
The world has encountered multiple pandemics and
public health emergencies in the last twenty years;
preparedness for the next crisis remains critical.
7

8. The first Point-of-Care Comprehensive
Syndromic Multiplex Diagnostic,
covering all essential viral and bacterial
targets with results in 60 seconds.
60-Second Comprehensive
Multiplex Diagnostic
Point-of-Care
Proof Of Concept For Future Partner Development
This is what Opteev’s Biosensor grows to with the right partner…
Instantly detects airborne pathogens
including COVID-19, Flu, & RSV, and
triggers air purification. Alerts when
air is clean.
Pathogen Sensor for Air
Purifiers & HVAC
Environmental
Monitoring
Detects & identifies harmful
foodborne pathogens for
ultra-fast & accurate food
safety analysis.
Foodborne Pathogen
Biosensor
Food Safety
Precisely detects respiratory
pathogens through breath
analysis. Know if you’re spreading
an infection in under 60 seconds.
Multiplex Breath
Analyzer
At-Home
Testing
TAM = $62–119 Billion TAM = $46–87 Billion TAM = $15–22 Billion TAM = $25–46 Billion
8
TAM = $148–274 Billion USD Globally

9. Current Solutions: A Comparative Overview (for Multiplex Diagnostics)
$85,000–$250,000 Equipment Cost
$125-200 Cost Per Test
3 - 8 Hour Run Time
24–72 Hours Turnaround Time for Result
Current Comprehensive Multiplex Syndromic Diagnostics
Today’s comprehensive multiplex diagnostics are large machines designed for labs (not Point-of-Care), take an average
turnaround time of 24–72 hours to provide results due to batch processing, and cost around $100,000 for the equipment.
Not Designed for Point-of-Care
9

10. Example of the Competitive Advantage (for Multiplex Diagnostics)
Result Time Price of Equipment Accessibility
24 – 72 Hours
60 Seconds
$100,000 & Up
Low-Cost
Designed for
Point-of-Care
Non-Portable
Laboratory
Equipment
Up to
99%
More
Affordable
Ultra-
Portable
Up to
99%
Faster
vs. Multiplex Diagnostic
with Opteev’s Biosensor
Current Multiplex
Diagnostics
Tomorrow’s diagnostics, enabled with Opteev’s Biosensor, will introduce the first ever comprehensive multiplex syndromic testing
available at the Point of Care. This transformative approach offers unmatched speed as well as unparalleled affordability and accessibility.
10

11. Validation
Research study on Opteev’s game-changing biosensor is available
online and is currently under peer-review for publication.
https://www.biorxiv.org/content/10.1101/2023.08.08.552470v1
11

12. Conrad Bessemer Dr. Biplab Pal
Dr. Mesfin Meshesha
Chairman & Co-Founder
Head of Virology & Diagnostics
Co-Founder & Research Director
Team
Mr. Bessemer is the
Chairman of Opteev and
leads all aspects of Opteev’s
overall operations. He is also
the CEO/Managing Partner of
Opteev’s parent company,
Novatec, Inc.
Dr. Pal oversees Opteev’s
multidisciplinary in-house
bioengineering and
engineering teams and drives
Opteev’s scientific innovation.
Dr. Meshesha oversees the
multiple subgroups of
Opteev’s Virology
Department, pathogen
research, and molecular
diagnostic technology
development.
Dana Gardner
Vice President, Business Development
Mr. Gardner manages
Opteev’s marketing
initiatives, portfolio strategy,
pipeline prioritization, and
formation of new business
ventures.
Opteev Technologies, Inc. is a Baltimore-based pioneering technology company at the forefront of
diagnostics with laboratories and facilities in Baltimore, MD, Naples, FL, San Diego, CA, and Kolkata, India.
In Collaboration With…
12

13. Potential Outcomes
Best Case Scenario
As market leaders in all potential applications, Opteev and its partner could achieve a dominant market
share in the total addressable market of $148-274 Billion, potentially generating revenues between
$59-109 Billion.
Realistic Scenario
By capturing just 10-15% of the potential revenue in our markets, Opteev and partner stand to gain a massive
Worst Case Scenario
In the event of rejection for FDA authorized applications and Opteev/Partner only tapping into a small
share of the $14-26.9 Billion air purifier market, a conservative licensing estimate presents an impressive
$420-$807 Million opportunity.
significantly impacting the fields of healthcare, air quality, & food safety.
$22-41 Billion,
13

14. Partnership Future
• Our aim is not merely to secure funding but to forge a strategic partnership with a
visionary entity that recognizes the transformative opportunity of our technology.
• We're seeking an ally with the expertise, resources, and facilities to efficiently
commercialize our biosensor’s applications and unlock their full potential.
• While we bring groundbreaking biosensor technology to the table, the right partner
will commercialize our technology and participate in massive revenue growth.
14

15. Partnership Benefits
• Saving Lives & Averting Future Pandemics
Our partnership holds the promise of protecting countless lives of children,
parents, and grandparents and offers society a fortified way of defending
against future pandemics.
The true value of our partnership goes far beyond financial gain.
• Leaving a Lasting Legacy & Safeguarding Generations
By joining forces with Opteev, we have the power to revolutionize global
health and create a transformation change that will resonate for
generations to come.
15

16. Join us in shaping the
future of diagnostics &
unlocking the potential of
Opteev’s Biosensor
Partnership Inquiries: partners@opteev.com
16

17. Sources:
Healthcare Point-of-Care
• Respiratory Diagnostics: $63.7 Billion USD Globally: https://www.grandviewresearch.com/industry-analysis/infectious-respiratory-disease-diagnostics-market-report#:~:text=b.-
,The%20global%20infectious%20respiratory%20disease%20diagnostics%20market%20size%20was%20estimated,USD%2050.4%20billion%20in%202022
• Point of Care Diagnostics: $48.93-78.11 Billion USD Globally: https://www.fortunebusinessinsights.com/industry-reports/point-of-care-diagnostics-market-101072
• STD Diagnostics: $9.52-16.68 Billion USD Globally: https://www.fortunebusinessinsights.com/industry-reports/sexually-transmitted-diseases-testing-market-101095
• GI Infection Diagnostics: $4.59-4.83 Billion USD Globally: https://www.grandviewresearch.com/industry-analysis/gastrointestinal-diagnostics-market-report#:~:text=b.-
,The%20global%20gastrointestinal%20diagnostics%20market%20size%20was%20valued%20at%20USD,USD%204.83%20billion%20in%202022.
• CNS Infection Diagnostics: $115.41 Million USD Globally: https://www.grandviewresearch.com/industry-analysis/meningitis-diagnostic-testing-market-report
At-Home Testing
• At-Home Diagnostics: $9.05-45.58 Billion USD Globally: https://www.globenewswire.com/en/news-release/2023/02/06/2602165/0/en/Global-At-Home-Testing-Market-Is-Expected-to-Reach-45-58-Billion-by-2031-Allied-Market-Research.html
Air Purifier / HVAC Integration:
• Air Quality Monitoring Global Market: $4.7 – 8.6 Billion USD Globally: https://www.globenewswire.com/news-release/2023/03/29/2637219/0/en/Air-Quality-Monitoring-Market-Size-Growing-at-6-4-CAGR-Set-to-Reach-USD-8-6-Billion-By-
2032.html#:~:text=The%20Global%20Air%20Quality%20Monitoring%20Market%20size%20in%202022%20stood,the%20lack%20of%20proper%20management
• Air Purifier Global Market: $13-26.72 Billion USD Globally: https://www.arizton.com/market-reports/air-purifier-market-size-analysis#:~:text=MARKET%20INSIGHTS,12.76%25%20during%20the%20forecast%20period.
• HVAC Global Market: $157.71-228.74 Billion USD Globally: https://www.fortunebusinessinsights.com/heating-ventilation-and-cooling-hvac-system-market-102664
Food Safety
• Foodborne Pathogen Detection: $15.1 -22.7 Billion USD Globally: https://www.marketsandmarkets.com/Market-Reports/food-pathogen-testing-market-202386163.html
Respiratory Infection Data
• CDC: 47 Million, or 1 in 3 antibiotic prescriptions, unnecessary each year: https://www.cdc.gov/media/releases/2016/p0503-unnecessary-prescriptions.html
• CDC: Majority of unnecessary antibiotic prescriptions are prescribed for respiratory conditions caused by viruses: https://www.cdc.gov/media/releases/2016/p0503-unnecessary-prescriptions.html
• CDC Director: “Antibiotics are lifesaving drugs, and if we continue down the road of inappropriate use we’ll lose the most powerful tool we have to fight life-threatening infections…”: https://www.cdc.gov/media/releases/2016/p0503-unnecessary-
prescriptions.html
• 100 Million Respiratory Infections Each Year: Grijalva CG, Wu SC, Uyeki TM. Respiratory infections in the United States: a review of the literature, 2014-2017. Rev Med Microbiol. 2018;29(2):53-74. doi:10.1097/MRM.0000000000000152
• 20 Million Respiratory Infection Hospitalizations Each Year: Grijalva CG, Wu SC, Uyeki TM. Respiratory infections in the United States: a review of the literature, 2014-2017. Rev Med Microbiol. 2018;29(2):53-74.
doi:10.1097/MRM.0000000000000152
• 1 Million Respiratory Infection Deaths Each Year: Grijalva CG, Wu SC, Uyeki TM. Respiratory infections in the United States: a review of the literature, 2014-2017. Rev Med Microbiol. 2018;29(2):53-74. doi:10.1097/MRM.0000000000000152
• Early diagnostics leads to reduction in hospitalizations/deaths: 1.Neuzil KM, Boeckh M, Mitchel EF Jr, et al. Effectiveness of oseltamivir treatment in children with influenza A or B infection. N Engl J Med. 2006;354(26):2637-2647.
doi:10.1056/NEJMoa052130
• Over 70% of respiratory infections treated based on symptoms alone: Fleming-Dutra KE, Harrison LH, Fleming PJ, et al. Syndromic treatment of respiratory infections in the United States. Clin Infect Dis. 2018;67(11):1742-1748.
doi:10.1093/cid/ciy584
17